ENTA

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Enanta Pharmaceuticals (ENTA - Research Report) today and set a price target of $137.00. The company's shares closed yesterday at $71.27.Buchanan covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, PolyPid, and Arbutus Biopharma. According to TipRanks, Buchanan has an average return of -9.1% and a 35.00% success rate on recommended stocks. In addition to JMP Securities, Enanta Pharmaceuticals also received a Buy from Piper Sandler's Yasmeen Rahimi in a report issued on July 29. However, on August 1, Oppenheimer maintained a Hold rating on Enanta Pharmaceuticals (NASDAQ: ENTA).
https://www.tipranks.com/news/blurbs/jmp-securities-keeps-their-buy-rating-on-enanta-pharmaceuticals-enta?utm_source=advfn.com&utm_medium=referral